CellSeed
Tokyo
About CellSeed
CellSeed develops regenerative medicine products primarily in Japan and Europe. The company offers regenerative medicines such as epithelial cell sheet for corneal and esophageal regeneration, regenerated cardiac patch to treat heart diseases, cell sheet for periodontal tissue regeneration, and regenerated cartilage sheet for the treatment of osteoarthritis The company was founded in 2001 and is headquartered in Tokyo, Japan.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $30.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2014)
- Ticker: tyo:7776
- Website: cellseed.com
Industries & Categories
Alternative Medicine, Biotechnology, Health Care
Canonical: https://fsome.com/organization/cellseed-1877287 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.